DUAL AND MULTIPLE PROTEINOPATHIES IN NEURODEGENERATIVE DEMENTIAS – RISK FACTORS, PROGNOSTIC INDICATORS AND CLINICAL RAMIFICATIONS
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
Dementia is the umbrella term used to refer to a number of different clinical presentations,each associated with distinct histopathological signatures of protein aggregates and spread.However, converging evidence now suggests the common co-occurences of dual/multiple proteinopathies across dementia syndromes.The present study will identify the clinical ramifications and factors that are most predictive for such proteinopathies in a large cohort of longitudinally-studied patients with dementia.
Vascular Cognitive Risk Score: Quantifying The Vascular Burden In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$627,180.00
Summary
What causes dementia in a patient presenting to a clinic is often uncertain. While there are exciting potential treatments in the pipeline, we need to understand the cause of the disease in a specific patient to make correct treatment decisions. Stroke and other vascular diseases of the brain cause a significant proportion of dementia in the community. Using MRI scanning technology, this project will quantify this burden in a given patient by developing a ‘vascular cognitive risk' (VCR) score.
Finding Clinical Predictors For The Underlying Pathology In Different Frontotemporal Dementia (FTD) Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$136,593.00
Summary
Due to the ageing population in Australia it is predicted that the prevalence of dementia will increase four-fold by 2050. Developing disease-modifying therapies for dementia is therefore a priority, however we also need to be able to accurately identify patients for whom these therapies will be beneficial. Here we will develop strategies for identifying patients with particular protein abnormalities in their brain, the substrate of most therapeutic interventions.
In Vivo Tau Imaging In Alzheimer’s Disease And Other Dementias
Funder
National Health and Medical Research Council
Funding Amount
$538,998.00
Summary
Alteration of the normal protein tau leads to its deposition inside the brain cells leading to their death. These deposits have been well characterized and they are associated with cognitive impairment. We propose to study tau deposits in vivo in humans using positron emission tomography (PET) and assess its association with cognition and other signs of neurodegeneration
Lewy Bodies In Patients With Dementia – Determining Common And Unique Mechanisms In Relation To Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
Alzheimer’s disease is the most common type of dementia but often has multiple mixed pathologies. For example, Alzheimer post mortem brains may have abnormal accumulation of Lewy bodies in certain parts of the brains, and could be diagnosed as Lewy body disease. This may represent a skewed representation of some dementia subtypes. This project will identify the biological determinants of dementia patients with Lewy body disease for better understanding and future therapeutic targeting.
Functional Genomics Approach To Extend Lifespan While Preventing Age-related Cognitive Decline
Funder
National Health and Medical Research Council
Funding Amount
$772,600.00
Summary
In our ageing population, preventing age-related neurological decline is one of the central medical challenges of the 21st century. Here we use human population data obtained from people who reached 90 years of age free of any disease, or patients who suffer from dementia, combined with functional genomics studies in animals to pinpoint new genes that can be targeted to extend lifespan while preserving neurological function in these extended years of life.
Feasibility Of Minimally Invasive Deep Brain Stimulation Via An Endovascular Stent-electrode.
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Neurocognitive decline in Parkinson's disease refers to the non-motor symptoms of the disease; these symptoms have increasingly become recognised as both prevalent, and evolving early in the disease course. While motor symptoms are treated with drugs and electrodes, the changes to patients� cognition, the progressive dementia, the psychosis and other symptoms progress with poor treatment. This research is designed to identify and understand targets so better treatments can be created.
Treating Parkinson's Disease Dementia With Nanoscaffolds
Funder
National Health and Medical Research Council
Funding Amount
$665,144.00
Summary
Several diseases, including Parkinson’s disease (PD), result in dementia. Currently, pharmacological therapy is the only treatment for PD dementia, which only offers symptomatic relief with diminished efficacy. Therefore, there is a need to develop new strategies that prevent or slow the onset of dementia. This study will utilize nanoscaffolds that facilitate the controlled delivery of therapeutic proteins to prevent or slow the death of neurons associated with dementia in PD patients.
An Investigation Of The Potential Association Between Sports Concussion And Neurodegenerative Disease In Collision Sports Athletes
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Traumatic brain injury (TBI) is increasingly recognised as a risk factor for dementia. Sports concussion is the mildest form of TBI, but occurs frequently in contact sports, with some players sustaining multiple concussions during their career. Despite the increased attention on this topic, it is not known whether repeated concussions during an athlete’s career lead to a greater vulnerability or a greater risk for dementia later in life. This research program aims to investigate these concerns.
Longitudinal Transcriptome Profiles For People With Dementia
Funder
National Health and Medical Research Council
Funding Amount
$475,913.00
Summary
Over the past decade, less than half a percent of drugs trialled for Alzheimer Disease were found to be effective. This highlights the need for new drug targets. This Fellowship aims to study how genes express themselves over time, among people with very high risk of dementia (genetic form of Alzheimer Disease and Huntington Disease). By looking at gene expression in nerve tissue in the nose, fluid around the brain, and blood, I hope to better understand the disease mechanisms causing dementia.